Integra LifeSciences Declines on FY Outlook Cut After Supply Chain Issues

Dow Jones

Oct 31, 2025

By Kelly Cloonan

Shares of Integra LifeSciences slid as the company cut its full-year outlook after supply chain interruptions dragged on revenue growth in its latest quarter.

The stock dropped 25% to $11.62 on Thursday. Shares are down 49% this year.

The medical technology company now forecasts adjusted earnings per share of $2.19 to $2.24 for the year, lowering the upper range of its prior projection of $2.19 to $2.29.

Integra also cut its revenue outlook, guiding for sales of $1.62 billion to $1.64 billion, compared to $1.66 billion to $1.68 billion previously.

The updated guidance comes after Integra said third-quarter revenue was negatively affected by two supply interruptions. Chief Executive Mojdeh Poul said the company is working to strengthen its supply chain and quality management system, and is confident it can improve overall performance.

For the third quarter, Integra narrowed its loss to $5.4 million, or 7 cents a share, from a loss of $10.7 million, or 14 cents a share, a year earlier.

Adjusted earnings per share were 54 cents, ahead of estimates of 43 cents a share according to analysts polled by FactSet.

Revenue rose 5.6% to $402.1 million, missing analyst expectations of $414.2 million.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

October 30, 2025 12:14 ET (16:14 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579124024"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579124024\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579124024?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579124024","market":"sh","top_or_hot":-1,"title":"Integra LifeSciences Declines on FY Outlook Cut After Supply Chain Issues","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Integra LifeSciences slid as the company cut its full-year outlook after supply chain interruptions dragged on revenue growth in its latest quarter. \n</p>\n<p>\n  The stock dropped 25% to $11.62 on Thursday. Shares are down 49% this year. \n</p>\n<p>\n  The medical technology company now forecasts adjusted earnings per share of $2.19 to $2.24 for the year, lowering the upper range of its prior projection of $2.19 to $2.29. \n</p>\n<p>\n  Integra also cut its revenue outlook, guiding for sales of $1.62 billion to $1.64 billion, compared to $1.66 billion to $1.68 billion previously. \n</p>\n<p>\n  The updated guidance comes after Integra said third-quarter revenue was negatively affected by two supply interruptions. Chief Executive Mojdeh Poul said the company is working to strengthen its supply chain and quality management system, and is confident it can improve overall performance. \n</p>\n<p>\n  For the third quarter, Integra narrowed its loss to $5.4 million, or 7 cents a share, from a loss of $10.7 million, or 14 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings per share were 54 cents, ahead of estimates of 43 cents a share according to analysts polled by FactSet. \n</p>\n<p>\n  Revenue rose 5.6% to $402.1 million, missing analyst expectations of $414.2 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 12:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Integra LifeSciences Declines on FY Outlook Cut After Supply Chain Issues</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntegra LifeSciences Declines on FY Outlook Cut After Supply Chain Issues\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-31 00:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Integra LifeSciences slid as the company cut its full-year outlook after supply chain interruptions dragged on revenue growth in its latest quarter. \n</p>\n<p>\n  The stock dropped 25% to $11.62 on Thursday. Shares are down 49% this year. \n</p>\n<p>\n  The medical technology company now forecasts adjusted earnings per share of $2.19 to $2.24 for the year, lowering the upper range of its prior projection of $2.19 to $2.29. \n</p>\n<p>\n  Integra also cut its revenue outlook, guiding for sales of $1.62 billion to $1.64 billion, compared to $1.66 billion to $1.68 billion previously. \n</p>\n<p>\n  The updated guidance comes after Integra said third-quarter revenue was negatively affected by two supply interruptions. Chief Executive Mojdeh Poul said the company is working to strengthen its supply chain and quality management system, and is confident it can improve overall performance. \n</p>\n<p>\n  For the third quarter, Integra narrowed its loss to $5.4 million, or 7 cents a share, from a loss of $10.7 million, or 14 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings per share were 54 cents, ahead of estimates of 43 cents a share according to analysts polled by FactSet. \n</p>\n<p>\n  Revenue rose 5.6% to $402.1 million, missing analyst expectations of $414.2 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 30, 2025 12:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579124024","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579124024","pubTimestamp":1761840840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Integra LifeSciences slid as the company cut its full-year outlook after supply chain interruptions dragged on revenue growth in its latest quarter.The stock dropped 25% to $11.62 on Thursday. Shares are down 49% this year.The medical technology company now forecasts adjusted earnings per share of $2.19 to $2.24 for the year, lowering the upper range of its prior projection of $2.19 to $2.29.Integra also cut its revenue outlook, guiding for sales of $1.62 billion to $1.64 billion, compared to $1.66 billion to $1.68 billion previously.The updated guidance comes after Integra said third-quarter revenue was negatively affected by two supply interruptions. Chief Executive Mojdeh Poul said the company is working to strengthen its supply chain and quality management system, and is confident it can improve overall performance.For the third quarter, Integra narrowed its loss to $5.4 million, or 7 cents a share, from a loss of $10.7 million, or 14 cents a share, a year earlier.Adjuste","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","IART":"英特格拉生命科学"},"translate_title":"Integra LifeSciences因供应链问题下调财年前景而股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IART":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Integra LifeSciences slid as the company cut its full-year outlook after supply chain interruptions dragged on revenue growth in its latest quarter. \n\n\n  The stock dropped 25% to $11.62 on Thursday. Shares are down 49% this year. \n\n\n  The medical technology company now forecasts adjusted earnings per share of $2.19 to $2.24 for the year, lowering the upper range of its prior projection of $2.19 to $2.29. \n\n\n  Integra also cut its revenue outlook, guiding for sales of $1.62 billion to $1.64 billion, compared to $1.66 billion to $1.68 billion previously. \n\n\n  The updated guidance comes after Integra said third-quarter revenue was negatively affected by two supply interruptions. Chief Executive Mojdeh Poul said the company is working to strengthen its supply chain and quality management system, and is confident it can improve overall performance. \n\n\n  For the third quarter, Integra narrowed its loss to $5.4 million, or 7 cents a share, from a loss of $10.7 million, or 14 cents a share, a year earlier. \n\n\n  Adjusted earnings per share were 54 cents, ahead of estimates of 43 cents a share according to analysts polled by FactSet. \n\n\n  Revenue rose 5.6% to $402.1 million, missing analyst expectations of $414.2 million. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 30, 2025 12:14 ET (16:14 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}